Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects (2014)
- Authors:
- USP affiliated authors: HIRATA, MARIO HIROYUKI - FCF ; RODRIGUES, ALICE CRISTINA - ICB ; DOREA, EGIDIO LIMA - HU ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidades: FCF; ICB; HU
- DOI: 10.1016/j.jacl.2014.02.008
- Subjects: POLIMORFISMO; COLESTEROL; FARMACOLOGIA; LIPÍDEOS; NUCLEOTÍDEOS; FARMACOGENÉTICA; LIPOPROTEÍNAS LDL; REAÇÃO EM CADEIA POR POLIMERASE; PLASMA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Journal of Clinical Lipidology
- ISSN: 1933-2874
- Volume/Número/Paginação/Ano: v. 8, n. 3, p. 256-264, 2014
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
ANDERSON, Jacqueline M. et al. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. Journal of Clinical Lipidology, v. 8, n. 3, p. 256-264, 2014Tradução . . Disponível em: https://doi.org/10.1016/j.jacl.2014.02.008. Acesso em: 25 set. 2024. -
APA
Anderson, J. M., Cerda, A., Hirata, M. H., Rodrigues, A. C., Dórea, E. L., Bernik, M. M. S., et al. (2014). Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects. Journal of Clinical Lipidology, 8( 3), 256-264. doi:10.1016/j.jacl.2014.02.008 -
NLM
Anderson JM, Cerda A, Hirata MH, Rodrigues AC, Dórea EL, Bernik MMS, Bertolami MC, Faludi AA, Hirata RDC. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects [Internet]. Journal of Clinical Lipidology. 2014 ; 8( 3): 256-264.[citado 2024 set. 25 ] Available from: https://doi.org/10.1016/j.jacl.2014.02.008 -
Vancouver
Anderson JM, Cerda A, Hirata MH, Rodrigues AC, Dórea EL, Bernik MMS, Bertolami MC, Faludi AA, Hirata RDC. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects [Internet]. Journal of Clinical Lipidology. 2014 ; 8( 3): 256-264.[citado 2024 set. 25 ] Available from: https://doi.org/10.1016/j.jacl.2014.02.008 - Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response
- Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin
- Expression of inflammatory response genes in pbmc from type 2 diabetes individuals treated with simvastatin and ezetimibe
- Leptin receptor gene polymorphisms are associated with adiposity and metabolic alterations in Brazilian individuals
- CYP3A4 and CYP3A5 mRNA expression in hypercholesterolemic individuals under hypolipemiant therapy
- Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients
- Relationships among CYP3A4 and CYP3A5 haplotypes, mRNA expression, CYP3A activity and atorvastatin response in hypercholesterolemic individuals
- Differentiation of african components of ancestry to stratify groups in a case-control study of a brazilian urban population
Informações sobre o DOI: 10.1016/j.jacl.2014.02.008 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas